44例rhTNFR:Fc治疗类风湿关节炎发生肺结核风险研究

Study on the Risk of Pulmonary Tuberculosis in 44 Cases of Rheumatoid Arthritis Treated with rhTNFR: Fc

目的:了解与DMARDs(抗风湿药)相比,rhTNFR:Fc(重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白)治疗类风湿关节炎发生肺结核的风险。方法:收集2015年9月至2017年9月大理大学第一附属医院352位类风湿关节炎患者的临床资料,按治疗药物分为DMARDs组(308例)和rhTNFR:Fc组(44例),对治疗24周和48周后的肺结核发病情况统计分析。结果:治疗24周和48周后,DMARDs组和rhTNFR:Fc组肺结核发病率及陈旧性肺结核复发率差异无统计学意义。结论:研究未发现rhTNFR:Fc相比DMARDs使类风湿关节炎患者肺结核发病风险增高。

Objective： To explore the risk of tuberculosis in patients with rheumatoid arthritis who were treated with rhTNFR： Fc instead of DMARDs. Methods： The clinical data of 352 patients with rheumatoid arthritis at the First Affiliated Hospital of Dali University from September 2015 to September 2017 were collected and divided into the DMARDs group（308 cases）and the rhTNFR：Fc group（44 cases）. The incidence of tuberculosis after 24-week and 48-week treatment was statistically analyzed. Results： After 24 weeks and 48 weeks of treatment, there were no statistical significances in the incidence of tuberculosis and the relapse rate of old tuberculosis between the DMARDs group and the rhTNFR：Fc group. Conclusion： This study shows that there is no higher risk of tuberculosis in patients with rheumatoid arthritis when treated with the rhTNFR：Fc than with the DMARDs.